A Phase I/II Clinical Trial Testing the Safety and Feasibility of IL-21-Expanded Natural Killer Cells for the Induction of Relapsed/Refractory Acute Myeloid Leukemia
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Natural killer cell therapy (Primary) ; Cytarabine; Filgrastim; Fludarabine
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 21 Jun 2021 Biomarkers information updated
- 17 Dec 2013 Planned End Date changed from 1 Oct 2020 to 1 May 2021 as reported by ClinicalTrials.gov.
- 17 Dec 2013 Planned initiation date changed from 1 Oct 2013 to 1 May 2014 as reported by ClinicalTrials.gov.